Terug naar bedrijfspagina

Nieuws over Hyloris Pharmaceuticals

12/06/2026 2026 06 - Bedrijfsbezoek Hyloris & Nyxoah

09/06/2026 2026 05 - Wanneer volgt de grote doorbraak?

30/04/2026 Hyloris - releases Annual Report 2025 (30.04.2026)

26/03/2026 Hyloris - Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position: a year of bold moves and breakthrough milestones (26.03.2026)

20/02/2026 Hyloris - Provides Update on FDA Review of Valacyclovir for Oral Suspension (20.02.2026)

20/01/2026 Hyloris - kondigt strategisch partnerschap aan met Orion voor zijn RTU Pantoprazol IV op de Europese markt (20.01.2026)

31/12/2025 Hyloris - Licenses European and Turkish Rights to Next-Generation Wilson’s Disease Candidate from ArborMed (31.12.2025)

30/12/2025 Hyloris - Announces Partnership with Rosemont Pharmaceuticals for Atomoxetine Oral Solution in the U.S. (30.12.2025)

12/12/2025 Hyloris - Receives Exclusive License Option for Innovative Topical Therapy for a Rare Genetic Skin Disorder (12.12.2025)

19/11/2025 Hyloris - Board of Directors appoints Stijn Van Rompay as CEO (19.11.2025)

14/11/2025 Hyloris - kondigt positieve klinische studieresultaten aan voor intraveneuze aspirine (14.11.2025)

24/11/2025 2025 09 - Lager resultaat, maar betere kwaliteit

28/10/2025 Hyloris - and Orion Partner to Bring Tranexamic Acid RTU to Key European Markets (28.10.2025)

27/10/2025 Hyloris - kondigt samenwerking aan met Grand Life Sciences Group voor HY-094 in China (27.10.2025)

25/09/2025 Hyloris - Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position (25.09.2025)

22/08/2025 Hyloris - Signs Exclusive Licensing Agreement with Huons Co., Ltd. for XTRAZA™ in South Korea (22.08.2025)

17/07/2025 Hyloris - Announces Positive Clinical Study Results for Atomoxetine Oral Solution (17.07.2025)

23/06/2025 Hyloris Partners - with Kuvatris Therapeutics to Advance Suramin IV (23.06.20235)

03/06/2025 Hyloris - Announces U.S. FDA Approval for Tranexamic Acid Ready-to-Use (RTU) (03.06.2025)

22/05/2025 Hyloris - Announces License Deal with AFT Pharmaceuticals for XTRAZA (22.05.2025)

13/05/2025 Hyloris - Announces Partnerships for Valacyclovir Oral Suspension Covering Canada, Australia, New Zealand and the Netherlands (13.05.2025)

01/05/2025 Hyloris - releases Annual Report 2024 (01.05.2025)

31/03/2025 Hyloris - Announces a New Product Candidate Targeting Iron Deficiency (31.03.2025)

20/03/2025 Hyloris Pharmaceuticals - Reports 2024 Results and Provides Business Outlook (20.03.2025)

19/03/2025 Hyloris - Announces Positive IDMC Recommendation to Continue Alenura® Study Following Interim Assessment (19.03.2025)

14/03/2025 Hyloris - Announces Positive Study Results for Dofetilide IV (14.03.2025)

25/02/2025 Hyloris - Announces FDA Acceptance of New Drug Application (NDA) for Valacyclovir Oral Liquid (25.02.2025)

13/02/2025 Hyloris - Broadens Pipeline with Ready-To-Use Pantoprazole IV (13.02.2025)

03/02/2025 Hyloris - Announces Partnership with Colonis Pharma for XTRAZA in the UK (03.02.2025)

07/08/2025 2025 02 - Herkansing

30/12/2024 Hyloris - Announces Positive Study Results for Valacyclovir Oral Suspension for European Markets (30.12.2024)

26/12/2024 Hyloris - Announces Partnership for U.S Commercialisation of Tranexamic Acid Ready-to-Use (RTU) (26.12.2024)

09/12/2024 Hyloris - Appoints Christophe Maréchal as Chief Financial Officer (09.12.2024)

09/12/2024 Hyloris - Announces Partnership with Rosemont Pharmaceuticals for Valacyclovir Oral Suspension in the U.S. (09.12.2024)

05/11/2024 2024 09 - Back to normal?

16/10/2024 FSMA- WAARSCHUWING MET BETREKKING TOT DE LAATTIJDIGE OPENBAARMAKING VAN HET HALFJAARLIJKS FINANCIEEL VERSLAG (16.10.2024)

06/10/2024 Hyloris Pharmaceuticals - Reports Preliminary 2024 Half-Year Results and provides Business Outlook (06.10.2024)

05/10/2024 Hyloris Pharmaceuticals - Reports Preliminary 2024 Half-Year Results and provides Business Outlook (05.10.2024)

01/10/2024 Hyloris - Annual General Shareholders Meeting was Held Today Communication of the 2024 Half-Year Results will be Delayed (01.10.2024)

30/09/2024 Hyloris - Announces Expansion of Maxigesic IV into China (30.09.2024)

16/09/2024 Hyloris - Arbitration Panel Issues Final Opinion in Dispute Between Hyloris Pharmaceuticals and AltaThera Pharmaceuticals (16.09.2024)

11/09/2024 Euronext - announces September 2024 quarterly review results of the BEL Family indices - announces September 2024 review results of the OBX Family (11.09.2024)

23/08/2024 Hyloris - Releases Invitation to its General Shareholders’ Meeting (23.08.2024)

19/08/2024 Hyloris - Expands Pipeline with a New Product Candidate for Equine Gastric Ulcer Syndrome (19.08.2024)

12/08/2024 Hyloris - Positive Clinical Results for Valacyclovir OS and Expansion of Territories outside of the US. (12.08.2024)

12/08/2024 HYLORIS - Positive Clinical Results for Valacyclovir OS and Expansion of Territories outside of the US. (12.08.2024)

02/08/2024 Hyloris - annonce sa nouvelle politique de communication (02.08.2024)

29/07/2024 Hyloris - Releases Annual Report 2023 (29.07.2024)

29/07/2024 Hyloris - publie son rapport annuel 2023 (30072024)

18/07/2024 Hyloris - Announces Expansion of Maxigesic IV into Brazil (18.07.2024)

08/07/2024 Hyloris - Update on Developments Following Completion of Forensic Independent Review with respect to QliniQ Transactions (08.07.2024)

06/07/2024 FSMA - WAARSCHUWING OVER DE INFORMATIE DIE HYLORIS PUBLICEERT (06.07.2024)

12/06/2024 Hyloris - shareholders approve all resolutions of the Extraordinary General Meeting by more than 99% and postpone the Annual General Meeting (12.06.2024)

13/05/2024 Hyloris - Update on the 2023 Annual Report and postponing of the Annual General Meeting (13.05.2024)

01/05/2024 Hyloris - Delays the Release of its Annual Report (01.05.2024)

05/04/2024 2024 04 Een goed 2024 tegemoet

14/03/2024 HYLORIS - Reports Full Year Results for 2023 & Provides Business Outlook - Communication at the request of the FSMA on the transactions with Qliniq (14.03.2024)

27/02/2024 Hyloris - Announces Launch of Maxigesic® IV in the U.S. and approval In Canada (27.02.2024)

14/02/2024 Hyloris - Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures (14.02.2024)

30/01/2024 Hyloris - and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) (30.01.2024)

30/01/2024 Hyloris - en Purna Female Healthcare kondigen positieve resultaten aan van Fase 2 studie bij patiënten met acute vulvovaginale candidiasis (VVC) (30.01.2024)

18/01/2024 Hyloris - verbreedt pijplijn met nieuw kandidaat-product voor Vulva Lichen Sclerosus (VLS) (18.01.2024)

16/01/2024 Hyloris - Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) (16.01.2024)

26/12/2023 Hyloris kondigt positieve klinische studieresultaten aan voor Valacyclovir orale suspensie (HY-029) (26.12.2023)

21/12/2023 Hyloris - verbreedt pijplijn met nieuw kandidaat-product voor het Burning Mouth Syndrome (21.12.2023)

04/12/2023 Hyloris - announces US FDA approval for Podofilox Gel (04.12.2023)

07/11/2023 ‘Er zit nog genoeg goed nieuws aan te komen’